These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27324149)

  • 21. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
    Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
    ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
    Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
    J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?
    Gratuze M; Joly-Amado A; Vieau D; Buée L; Blum D
    Neuroendocrinology; 2018; 107(2):181-195. PubMed ID: 29439247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
    Hasegawa M
    Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
    Hirata-Fukae C; Li HF; Hoe HS; Gray AJ; Minami SS; Hamada K; Niikura T; Hua F; Tsukagoshi-Nagai H; Horikoshi-Sakuraba Y; Mughal M; Rebeck GW; LaFerla FM; Mattson MP; Iwata N; Saido TC; Klein WL; Duff KE; Aisen PS; Matsuoka Y
    Brain Res; 2008 Jun; 1216():92-103. PubMed ID: 18486110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
    Liščić RM
    Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease.
    Li Y; Tsui W; Rusinek H; Butler T; Mosconi L; Pirraglia E; Mozley D; Vallabhajosula S; Harada R; Furumoto S; Furukawa K; Arai H; Kudo Y; Okamura N; de Leon MJ
    J Nucl Med; 2015 Feb; 56(2):270-3. PubMed ID: 25572087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Amyloid Positron Emission Tomography in the Therapeutic Strategies for Alzheimer's Disease].
    Ishii K
    Brain Nerve; 2017 Jul; 69(7):809-818. PubMed ID: 28739995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
    Smith R; Wibom M; Olsson T; Hägerström D; Jögi J; Rabinovici GD; Hansson O
    J Alzheimers Dis; 2016; 51(2):339-43. PubMed ID: 26836192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tau-imaging in neurodegeneration.
    Bischof GN; Endepols H; van Eimeren T; Drzezga A
    Methods; 2017 Nov; 130():114-123. PubMed ID: 28790016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Tau and Its Ligands in PET Imaging.
    Harada R; Okamura N; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Biomolecules; 2016 Jan; 6(1):7. PubMed ID: 26751494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.